My conclusion: clearly there is a clinically meaningful benefit in patients who require supplemental oxygen but not higher levels of respiratory support.
Personally I would also use it in critically severe disease *if supply was not a constraint*. But unfortunately it is.
Thanks to the US “me-first” approach to hoarding remdesivir, minuscule supplies are available in Canada.
We were allocated 30 courses for the *entire province* (4.5 million people) outside of a clinical trial (which is not an option at most hospitals)
A reminder of how the 🇺🇸🇨🇦 HCQ PEP trial came to be through #IDTwitter.
We didn’t have any details of how or if this would work... Todd just decided to get it done, adapting David’s protocol to Canada with support from colleagues in Manitoba & Alberta.